These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7550393)

  • 21. Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250.
    Steffens MG; Oosterwijk-Wakka JC; Zegwaart-Hagemeier NE; Boerman OC; Debruyne FM; Corstens FH; Oosterwijk E
    Anticancer Res; 1999; 19(2A):1197-200. PubMed ID: 10368675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.
    Luiten RM; Coney LR; Fleuren GJ; Warnaar SO; Litvinov SV
    Br J Cancer; 1996 Sep; 74(5):735-44. PubMed ID: 8795576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal antibody-targeted radiotherapy of renal cell carcinoma using a nude mouse model.
    Chiou RK; Vessella RL; Limas C; Shafer RB; Elson MK; Arfman EW; Lange PH
    Cancer; 1988 May; 61(9):1766-75. PubMed ID: 2451555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Technology evaluation: WX-G250, Wilex/Ludwig Institute for Cancer Research.
    Kennett RH
    Curr Opin Mol Ther; 2003 Feb; 5(1):70-5. PubMed ID: 12669474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two-step radio-immunotargeting of renal-cell carcinoma xenografts in nude mice with anti-renal-cell-carcinoma X anti-DTPA bispecific monoclonal antibodies.
    Kranenborg MH; Boerman OC; Oosterwijk-Wakka JC; de Weijert MC; Corstens FH; Oosterwijk E
    Int J Cancer; 1998 Jan; 75(1):74-80. PubMed ID: 9426693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer.
    Divgi CR; O'Donoghue JA; Welt S; O'Neel J; Finn R; Motzer RJ; Jungbluth A; Hoffman E; Ritter G; Larson SM; Old LJ
    J Nucl Med; 2004 Aug; 45(8):1412-21. PubMed ID: 15299069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical analysis of intratumoral heterogeneity of [131I]cG250 antibody uptake in primary renal cell carcinomas.
    Steffens MG; Oosterwijk E; Zegwaart-Hagemeier NE; van't Hof MA; Debruyne FM; Corstens FH; Boerman OC
    Br J Cancer; 1998 Nov; 78(9):1208-13. PubMed ID: 9820182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg.
    Bauer S; Oosterwijk-Wakka JC; Adrian N; Oosterwijk E; Fischer E; Wüest T; Stenner F; Perani A; Cohen L; Knuth A; Divgi C; Jäger D; Scott AM; Ritter G; Old LJ; Renner C
    Int J Cancer; 2009 Jul; 125(1):115-23. PubMed ID: 19384924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma.
    Maraveyas A; Stafford N; Rowlinson-Busza G; Stewart JS; Epenetos AA
    Cancer Res; 1995 Mar; 55(5):1060-9. PubMed ID: 7866989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.
    van Schaijk FG; Broekema M; Oosterwijk E; van Eerd JE; McBride BJ; Goldenberg DM; Corstens FH; Boerman OC
    J Nucl Med; 2005 Jun; 46(6):1016-22. PubMed ID: 15937314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human non-small-cell carcinoma of the lung.
    Stein R; Goldenberg DM; Thorpe SR; Mattes MJ
    J Nucl Med; 1997 Mar; 38(3):391-5. PubMed ID: 9074526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radioimmunoscintigraphy and radioimmunotherapy of renal cell carcinoma xenografts.
    Vessella RL; Alvarez V; Chiou RK; Rodwell J; Elson M; Palme D; Shafer R; Lange P
    NCI Monogr; 1987; (3):159-67. PubMed ID: 3821914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.
    Bleumer I; Knuth A; Oosterwijk E; Hofmann R; Varga Z; Lamers C; Kruit W; Melchior S; Mala C; Ullrich S; De Mulder P; Mulders PF; Beck J
    Br J Cancer; 2004 Mar; 90(5):985-90. PubMed ID: 14997194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison.
    Brouwers AH; Buijs WC; Oosterwijk E; Boerman OC; Mala C; De Mulder PH; Corstens FH; Mulders PF; Oyen WJ
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3953S-60S. PubMed ID: 14506194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts.
    van Dijk J; Uemura H; Beniers AJ; Peelen WP; Zegveld ST; Fleuren GJ; Warnaar SO; Oosterwijk E
    Int J Cancer; 1994 Jan; 56(2):262-8. PubMed ID: 8314310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biodistribution and radioimmunotherapy of SCCHN in xenotransplantated SCID mice with a 131I-labelled anti-EpCAM monoclonal antibody.
    Andratschke M; Gildehaus FJ; Johannson V; Schmitt B; Mack B; Reisbach G; Lang S; Lindhofer H; Zeidler R; Wollenberg B; Luebbers CW
    Anticancer Res; 2007; 27(1A):431-6. PubMed ID: 17352264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radioimmunotherapy of orthotopically transplanted pancreatic cancer with 131I-labeled chimeric monoclonal antibody Nd2.
    Yamamoto A; Sawada T; Yamashita Y; Nishihara T; Ho JJ; Kim Y; Chung KH
    Oncol Rep; 1999; 6(1):179-84. PubMed ID: 9864424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs.
    Stein R; Juweid M; Mattes MJ; Goldenberg DM
    Cancer Biother Radiopharm; 1999 Feb; 14(1):37-47. PubMed ID: 10850286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.
    Chong G; Lee FT; Hopkins W; Tebbutt N; Cebon JS; Mountain AJ; Chappell B; Papenfuss A; Schleyer P; U P; Murphy R; Wirth V; Smyth FE; Potasz N; Poon A; Davis ID; Saunder T; O'keefe GJ; Burgess AW; Hoffman EW; Old LJ; Scott AM
    Clin Cancer Res; 2005 Jul; 11(13):4818-26. PubMed ID: 16000579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody-mediated endocytosis of G250 tumor-associated antigen allows targeted gene transfer to human renal cell carcinoma in vitro.
    Dürrbach A; Angevin E; Poncet P; Rouleau M; Chavanel G; Chapel A; Thierry D; Gorter A; Hirsch R; Charpentier B; Senik A; Hirsch F
    Cancer Gene Ther; 1999; 6(6):564-71. PubMed ID: 10608353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.